Type 2 diabetes mellitus: current international guidelines, personalized approach and real outpatient practice

Main Article Content

V.I. Pankiv


According to experts from the International Diabetes Federation, the total number of people with diabetes mellitus (DM) will increase from 463 million in 2019 to 578 million in 2030 and to 700 million in 2045. In the context of the COVID-19 pandemic, patients with type 2 DM are more vulnerable to infection and severe pathology. Approaches to the choice of antihyperglycemic therapy to achieve ideal glycemic status are changing, given the emergence of new data on the pathogenesis of DM complications. Nowadays, the concept is adopted about individualization of antihyperglycemic therapy, i.e. the selection of treatment regimens based on information about a particular patient, the course and risk of developing diabetic complications. Given the increase in the proportion of elderly people, the treatment of type 2 DM in this age group is one of the important medical and social problems. Antihyperglycemic therapy in this population is difficult due to the increased risk of hypoglycemia, the presence of multiorgan and comorbid pathology, which significantly affects the course of type 2 DM. The literature review considers the issues of adequate prescription of drugs, in particular dipeptidyl peptidase-4 inhibitors. The presence of the expected hypoglycemic effect without the risks of hypoglycemia, good tolerability, favorable cardiovascular potential allows their widespread use in the elderly and senile patients with type 2 DM. The focus of the review is made on the VERIFY study that found that early combination therapy with vildagliptin and metformin reduces the risk of glycemic control loss by 49 %, exceeds the strategy of gradual intensification, provides stable control of glycated hemoglobin for 5 years, ensures its consistently low level, which is especially important in the first year of therapy to slow the progression of type 2 DM complications. Therefore, early combination therapy with vildagliptin and metformin in patients with type 2 DM has advantages over the strategy of gradual intensification.

Article Details

How to Cite
Pankiv, V. “Type 2 Diabetes Mellitus: Current International Guidelines, Personalized Approach and Real Outpatient Practice”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 6, Oct. 2020, pp. 463-70, doi:10.22141/2224-0721.16.6.2020.215384.
Literature Review


International Diabetes Federation (IDF). IDF Diabetes Atlas 2019. 9th ed. Brussels: IDF; 2019. 178 p.

Bloomgarden ZT. Diabetes and COVID-19. J Diabetes. 2020 Apr;12(4):347-348. doi:10.1111/1753-0407.13027.

Tamayo T, Rosenbauer J, Wild SH, et al. Diabetes in Europe: an update. Diabetes Res Clin Pract. 2014 Feb;103(2):206-17. doi:10.1016/j.diabres.2013.11.007.

American Diabetes Association (IDA). Standards of Medical Care in diabetes - 2020. Diabetes Care. 2020; 43(Suppl 1):207-212. doi:10.2337/dc20-in01.

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486.

Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. Prz Menopauzalny. 2017 Jun;16(2):38-43. doi:10.5114/pm.2017.68589.

Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012 May;42(5):484-91. doi:10.1111/j.1445-5994.2012.02758.x.

Huyen TV. Association between diabetes mellitus and urinary incontinence in elderly patients. Diabetes. 2018;67(Suppl 1):1481. doi:10.2337/db18-1481-P.

International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2017 Jan;60(1):3-6. doi:10.1007/s00125-016-4146-6.

Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016 May;39(5):694-700. doi:10.2337/dc15-2322.

Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care. 2010 May;33(5):1055-60. doi:10.2337/dc09-1597.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-1379. doi:10.2337/dc12-0413.

Pankiv VI. Association between metformin use and vitamin B12 deficiency in patients with type 2 diabetes. Mìžnarodnij endokrinologìčnij žurnal. 2019;15(1):47-54. doi:10.22141/2224-0721.15.1.2019.158691. (in Ukrainian).

Sircar M, Bhatia A, Munshi M. Review of hypoglycemia in the older adult: clinical implications and management. Can J Diabetes. 2016 Feb;40(1):66-72. doi:10.1016/j.jcjd.2015.10.004.

Li H, Shi FH, Huang SY, Zhang SG, Gu ZC. Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2018 Aug;97(32):e11853. doi:10.1097/MD.0000000000011853.

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi:10.1111/dom.12591.

Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013 Oct;14(15):2047-58. doi:10.1517/14656566.2013.824966.

He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi:10.2165/11598080-000000000-00000.

Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. Front Immunol. 2019 May 9;10:1050. doi:10.3389/fimmu.2019.01050.

Gong Q, Rajagopalan S, Zhong J. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function. Int J Cardiol. 2015 Oct 15;197:170-9. doi:10.1016/j.ijcard.2015.06.076.

Wang T, McNeill AM, Chen Y, O'Neill EA, Engel SS. Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. Diabetes Ther. 2018 Feb;9(1):309-315. doi:10.1007/s13300-017-0360-6.

Singh H, Chakrawarti A, Singh H, Guruprasad P, Gupta YK. Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study. J Family Med Prim Care. 2018 Jan-Feb;7(1):70-76. doi:10.4103/jfmpc.jfmpc_89_17.

Liu J, Tang Y, Hannachi H, Engel SS, Rajpathak S. Impact of switching from sulfonylureas to dipeptidyl peptidase-4 inhibitors on hypoglycemia burden in the united states - a predictive modeling approach. Diabetes. 2018;67(Suppl 1):385. doi:10.2337/db18-385-P.

McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015 Nov;17(11):1085-92. doi:10.1111/dom.12548.

Hyc’ A. Management of patients with diabetes mellitus. Ukrainian Medical Journal. 2020;(135):23. (in Ukrainian).

Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 Oct 26;394(10208):1519-1529. doi:10.1016/S0140-6736(19)32131-2.

Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019 Mar;42(3):416-426. doi:10.2337/dc17-1144.

Laiteerapong N, Karter AJ, Moffet HH, et al. Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study. J Diabetes Complications. 2017 Jan;31(1):94-100. doi:10.1016/j.jdiacomp.2016.07.023.


Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>